Researchers Create Nasal Vaccine to Combat Drug-Resistant Tuberculosis
Photo: CDC / Unsplash
Scientists at Johns Hopkins Medicine have developed an innovative nasal vaccine that could transform tuberculosis treatment by targeting drug-tolerant bacteria that survive standard antibiotics. By combining two TB genes, this therapeutic approach aims to strengthen the immune system's ability to eliminate persistent infections that cause the disease to resurface. This breakthrough offers new hope against a pathogen that remains the world's deadliest infectious disease.
Scientists at Johns Hopkins Medicine have developed an innovative nasal vaccine that could transform tuberculosis treatment by targeting drug-tolerant bacteria that survive standard antibiotics. By combining two TB genes, this therapeutic approach aims to strengthen the immune system’s ability to eliminate persistent infections that cause the disease to resurface. This breakthrough offers new hope against a pathogen that remains the world’s deadliest infectious disease.